Proto Labs, Inc. PRLB 深 滬
等待開盤 10-29 09:30:00 美东时间
53.49
-0.860
-1.58%
華盛通- 最 高54.62
- 今 開54.15
- 成交量 13.56万股
- 最 低 53.12
- 昨 收 54.35
- 總市值 12.77亿
- 52周最高 55.90
- 市盈率 靜 81.28
- 換手率 0.57%
- 52周最低 29.585
- 委 比 50.00%
- 總股本 2387.48万
- 歷史最高 286.57
- 量 比 0.73
- 振 幅 2.76%
- 歷史最低 22.04
- 每 手 1
- 風險率 5.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protolabs Introduces Advanced Features For Its Automated CNC Machining Service, Enabling Engineers And Product Developers To Access High-Quality Metal And Plastic Parts With Tighter Tolerances, Diverse Finishes, And Fast, Comprehensive Quality Documentation
Protolabs has announced the launch of advanced features within its automated CNC machining service, designed to empower engineers and product developers with reliable, high-quality milled parts at speed.The expanded
10-16 21:07
ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025
ProPhase Labs Inc. will participate in Renmark Financial Communications' virtual non-deal roadshow on September 4, 2025, to discuss its investor presentation, which includes updates on its crypto treasury strategy, potential liquidity events, and the cancellation of the Equity Line of Credit (ELOC). Investors can register for the live event or access the replay post-event via the provided link. The event will feature Ted Karkus, the company's Cha...
09-03 12:00
ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
ProPhase Labs, Inc. has been granted U.S. Patent No. 12379378-B2 for its biomarker-based systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma. This follows the successful validation of its BE-Smart™ molecular diagnostic, achieving over 95% technical success and compatibility with both brush and forceps biopsies, enhancing early detection. The patent, developed by inventors Joe Abdo, Sumeet K. Mittal,...
08-12 12:00
Proto Labs shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 sales guidance above estimates.
Proto Labs shares are trading higher after the company reported better-than-exp...
07-31 20:57
Proto Labs Sees Q3 Adj EPS $0.35-$0.43 vs $0.37 Est; Sees Sales $130M-$138M vs $129.652M Est; Sees Q3 GAAP EPS $0.17-$0.25 vs $0.20 Est
Third Quarter 2025 OutlookIn the third quarter of 2025, the Company expects to generate revenue between $130.0 million and $138.0 million.The Company expects third quarter 2025 diluted net income per share between $0.17
07-31 18:02
Earnings Scheduled For July 31, 2025
Companies Reporting Before The Bell • Vanguard Extended Duration Treasury ETF (...
07-31 16:32
Here are the major earnings before the open Thursday
Major earnings expected before the bell on Thursday include: AbbVie (OTC:ABBY) Bristol-Myers Squibb Company (BMY) Mastercard Incorporated (MA) CVS Health Corporation (CVS) Shell plc (SHEL) Other earni...
07-31 06:00
Proto Labs Extends Consulting Agreement with Former CEO
Proto Labs ( ($PRLB) ) has shared an update. On May 20, 2025, Robert Bodor step...
05-31 04:52
Proto Labs announces CEO, president appointment; reaffirms guidance
Proto Labs (NYSE:PRLB) has appointed Suresh Krishna as president and chief executive officer and a member of the board, effective immediately. Krishna most recently served as president and CEO at Nort...
05-22 04:22
Proto Labs Reaffirms Q2 Revenue Outlook Of $124.0M - $132.0M; Still Sees Q2 GAAP EPS Of $0.11 - $0.19, And Non-GAAP EPS Between $0.30 And $0.38
Reaffirms Second Quarter 2025 OutlookProto Labs, Inc. ("Protolabs" or the "Company") (NYSE:PRLB), the world's leading provider of digital manufacturing services, today announced its Board of Directors has appointed
05-22 04:14
